Can your own stem cells repair MS nerve damage? new trial aims to find out

NCT ID NCT04749667

Ongoing Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes in nerve signals, vision, and MRI scans to see if the treatment is safe and shows any signs of repair.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient's own bone marrow stem cells (mesenchymal stem cells)
What this could lead to: If it works, this could point toward a treatment that repairs nerve damage and slows or reverses disability in progressive multiple sclerosis.
What could go wrong: This is a very early, small study (18 people) testing safety and basic effectiveness. Many early-stage stem cell trials do not lead to approved treatments, and there are risks from the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Locations

Akershus university hospital

Lørenskog, Akershus, Norway
Haukeland University Hospital

Bergen, Vestland, Norway
St.Olav university hospital

Trondheim, Trøndelag, Norway
University hospital of North Norway

Tromsø, Troms Og Finnmark, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.